Deborah Autor Sells Shares of Hims & Hers Health

Deborah Autor, the Chief Policy Officer at Hims & Hers Health, Inc., recently sold 3,656 shares of the company. The transaction, which took place on June 11, 2026, was not part of a pre-planned trading program. This move comes as the company's stock trades at $26.82 on the NYSE.

Other Institutional Activity in Hims & Hers Health

Several institutional investors have also been active in Hims & Hers Health. BlackRock, Inc. trimmed its holdings by 236,346 shares, ending with 26,337,158 shares valued at about $546.76 million. On the other hand, Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both initiated positions, each acquiring 10,183,813 and 9,339,711 shares respectively, valued at $211.42 million and $193.89 million. Morgan Stanley significantly increased its stake by 4,959,856 shares, bringing its total to 8,889,088 shares worth $184.54 million. Meanwhile, State Street Corp added 154,498 shares, totaling 7,460,023 shares valued at $154.87 million.

Hims & Hers Health Stock Snapshot

Shares of NYSE:HIMS are currently trading near $26.82. The company has a market cap of approximately $6.21 billion and a forward P/E ratio of 30.13. With a beta of 2.398, the stock has experienced a 52-week low of $13.74 and a high of $70.43. Its 50-day moving average stands at $25.63, while the 200-day moving average is $33.57. The company maintains a current ratio of 1.689 and a quick ratio of 1.455, with a debt-to-equity ratio of 253.725.

Recent Earnings

Hims & Hers Health reported revenue of $2.37 billion with a growth of 3.8%. Despite this, the company posted a net margin of -0.56% and a return on equity of -2.66%. The next earnings release is scheduled for August 10, 2026.

Insider Buying and Selling at Hims & Hers Health, Inc.

In addition to Deborah Autor's transaction, there have been other recent insider activities. Christopher Payne sold 10,687 shares on June 15, 2026, while Anja Manuel sold 10,040 shares on the same day. David Wells executed both a sale of 957 shares and a purchase of the same amount on June 15, 2026. Patrick Harrison Carroll, the Chief Medical Officer, also sold 435 shares on June 15, 2026.

Analysts Set New Price Targets

Analysts have been active with their ratings on Hims & Hers Health. On May 26, 2026, B of A Securities maintained a 'hold' rating with a $25.00 price target. Truist Securities also maintained a 'hold' rating with a $23.00 target on May 22, 2026. JP Morgan initiated coverage with a 'buy' rating and a $35.00 target on April 24, 2026. The consensus among analysts is a 'hold' with a target mean price of $26.61, based on 14 opinions.

About Hims & Hers Health

Hims & Hers Health, Inc. operates as a health and wellness platform connecting consumers with healthcare professionals. The company offers various prescription and non-prescription products, focusing on wellness, skincare, and sexual health. Headquartered in San Francisco, California, it serves markets in the U.S., UK, Canada, and beyond. The company is led by CEO Andrew Dudum and employs over 2,400 people.

Bottom Line

Deborah Autor's recent sale of Hims & Hers Health shares is part of ongoing insider activity at the company. Investors track such transactions to gauge insider sentiment. Hims & Hers Health continues to show active institutional interest, with recent analyst ratings reflecting a cautious outlook. As always, 13F filings and insider transactions provide a snapshot of historical activity and may not represent current positions.